# **Special Issue**

# Homage to Jan Svoboda: Recent Advances in Topics Pioneered by his Prague School

## Message from the Guest Editors

Jan Svoboda, a pioneer of retrovirology, brilliant scientist and good friend passed away on March 13 this year. He was a living legend in the fields of retrovirology. tumor viruses, and oncogenes. The scientific community will remember Svoboda not only for his seminal work. Numerous students and peers will surely remember him also for his mentorship, life-long contacts, and influence. This Special Issue intends to commemorate Jan's scientific legacy and point out the recent progress in the topics that he established and pursued during his long and fruitful life in science. We also hope to assemble contributions from people who were influenced by Jan, either as his students or collaborators, and who now work on different topics of virology, oncology, immunology, and cell biology. We accept research articles, reviews, and, potentially, brief communications analysing Jan Svoboda's contribution to the basic concepts in virology. Jiri Hejnar Tomas Ruml

### **Guest Editors**

Dr. Jiri Heinar

Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic

Dr. Tomas Ruml

Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Prague, Czech Republic

### Deadline for manuscript submissions

closed (31 October 2018)



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/9293

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

